MTVA MetaVia Inc.

Nasdaq metaviatx.com


$ 0.74 $ -0.12 (-14.29 %)    

Monday, 10-Nov-2025 11:46:16 EST
QQQ $ 617.42 $ -1.38 (-0.22 %)
DIA $ 469.98 $ -1.87 (-0.4 %)
SPY $ 675.58 $ -1.60 (-0.24 %)
TLT $ 89.42 $ -0.07 (-0.08 %)
GLD $ 376.23 $ 0.28 (0.07 %)
$ 0.9082
$ 0.80
$ 0.72 x 1
$ 0.74 x 100
$ 0.70 - $ 0.80
$ 0.56 - $ 2.99
43,478,533
na
21.99M
$ 0.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 04-15-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
22 08-11-2020 06-30-2020 10-Q
23 05-20-2020 03-31-2020 10-Q
24 03-30-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 03-20-2018 12-31-2017 10-K
33 11-13-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-21-2017 12-31-2016 10-K
37 11-02-2016 09-30-2016 10-Q
38 09-14-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 43...

Core News & Articles

MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today anno...

Core News & Articles

MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today anno...

Core News & Articles

HC Wainwright & Co. analyst Andrew S. Fein assumes MetaVia (NASDAQ:MTVA) with a Buy rating and announces Price Target of...

Core News & Articles

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16...

Core News & Articles

Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential ofMetaVia's Oral GPR119 Ag...

Core News & Articles

Top-Line Data Expected in the Fourth Quarter of 2025CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION